Home> Threat of AMD > Clinical Trials> AREDS2 ForeseeHome Age-Related Eye Disease Study

AREDS2 Age-Related Eye Disease Study

The National Eye Institute, a division of the U.S. National Institutes of Health, has invited Notal Vision to  sponsor an ancillary study to the second Age-Related Eye Disease Study (AREDS2) using the ForeseeHome™ AMD Monitor.   The overall objective of this randomized clinical trial is to determine if home monitoring using the ForeseeHome AMD Monitor improves detection of wet AMD when compared with standard care.

Patients currently enrolled in the AREDS2 study may be eligible to participate in the ForeseeHome study.   This ForeseeHome study is also open to eligible patients who are not currently enrolled in AREDS2 at participating sites.

 

 

Eligibility

 

Participants must meet the following eligibility requirements:

Must be 55 years of age or older Must have intermediate age-related macular degeneration in at least one eye Must have corrected visual acuity of at least 20/60 or better in the study eye Must demonstrate successful use of the ForeseeHome device Must understand the study protocol and sign informed consent Must agree to communication with Notal Vision Must consent to examination by study ophthalmologist as needed Click here to view a list of the participating AREDS2 sites.

Experience the ForeseeHome